Titration of OCA based on therapeutic response and tolerability mitigated pruritus while maintaining efficacy. Disclosures: Christopher
L. Bowlus – Advisory Committees or Review Panels: Gilead Sciences, Inc; Consulting: Takeda; Nutlin-3 nmr Grant/Research Support: Gilead Sciences, Inc, Intercept Pharmaceuticals, Bristol Meyers Squibb, Lumena; Speaking and Teaching: Gilead Sciences, Inc Paul J. Pockros – Advisory Committees or Review Panels: Janssen, Merck, Genentech, BMS, Gilead, Boehinger Ingelheim, AbbVioe; Consulting: Genentech, Lumena, Regulus, Beckman Coulter, RMS; Grant/Research Support: Novartis, Intercept, Janssen, Genentech, BMS, Gilead, Vertex, Boehinger Ingelheim, Lumena, Beckman Coulter, AbbVie, RMS, Novartis, Merck; Speaking and Teaching: Genentech, BMS, Gilead Karel J. van Erpecum – Advisory Committees or Review Panels: Bristol Meyers Squibb, Abbvie Mitchell L. Shiffman – Advisory Committees or Review Panels: Merck, Gilead, Boehringer-Ingelheim, Bristol-Myers-Squibb, Abbvie, Janssen; Consulting: Roche/ Genentech, Gen-Probe; Grant/Research Support: Merck, Gilead, Boehringer-Ingelheim, Bristol-Myers-Squibb, GSK, Abbvie, Beckman-Coulter, Achillion, Lumena, Intercept, Novarit, Gen-Probe; Speaking and Teaching: Roche/Genentech, Merck, Gilead, GSK, Janssen, Bayer Frederik Nevens – Consulting: CAF, Intercept, Gore, BMS, Abbvie, Novartis, MSD, Small molecule library Eumedica, Janssen; Grant/Research
Support: Ipsen, Roche, MSD, Astellas Richard Pencek – Employment: Intercept Pharmaceuticals; Stock Shareholder: Intercept Pharmaceuticals Roya Hooshmand-Rad – Employment: Intercept pharmaceuticals Inc. David Shapiro – Employment: Inttercept Pharmaceuticals The following people have nothing to disclose: Joost Drenth, Annarosa Floreani, Catherine Vincent, Velimir A. Luketic, Victor Vargas Background: Sclerosing cholangitis in critically ill patients (SC-CIP) is a progressive biliary disease developing in a subgroup of patients during intensive care treatment. click here It is characterized by biliary casts/obliteration, formation of strictures and destruction
of intrahepatic bile ducts consecutively leading to liver cirrhosis and liver failure. Aim of the study was to characterize clinical course, outcome and prognostic features of patients with SC-CIP. Patients and Methods: 49 patients (34 male, age: 46.0+14.2, (mean+SD, years)) with SC-CIP, diagnosed by endoscopic retrograde cholangiography (ERC) were retrospectively analyzed. No patient had evidence of preexisting hepato-biliary disease or inflammatory bowel disease. Histological evaluation of liver biopsies, ICU and endoscopic treatment as well as outcome were evaluated. Results: Respiratory failure (N=11), severe polytrauma (N=9), sepsis (N=7), lung transplantation (N=5), surgery (N=5), cardiopulmonary rescuscitation (N=4) and burn injuries (N=3), were the most common reasons for hospitalization.